Abstract
Influenza vaccine is recommended for HIV-1-infected patients. The present prospective study was conducted to evaluate the clinical efficacy and immunologic responses to the vaccine, From November 1 to December 27, 2002, 262 HIV-1-infected patients received a trivalent influenza subunit vaccine, whereas 66 did not. Influenza illness occurred in 16 vaccinated and 14 nonvaccinated patients (incidence = 6.1% [95% confidence interval (CI): 4%-10%] in vaccinated vs. 21.2% [CI: 13%-35%] in nonvaccinated persons, P < 0.001; relative risk = 0.29 [CI: 0.14-0.55]). Influenza vaccine provided clinically effective protection against influenza illness in HIV-1-infected patients. In baseline antibody-negative patients, anti-H1 and anti-H3 antibody responses to the vaccination were significant in those patients with a CD4 count > 200 cells/μL compared with those with a CD4 count <200 cells/μL (P < 0.05). In contrast, in baseline antibody-positive patients, good antibody responses were observed irrespective of CD4 counts, like the healthy controls. Based on these results, annual vaccination is recommended. Specific CD4 responses correlated with HIV-1 viral load (VL), especially in patients treated with highly active antiretroviral therapy (HAART) compared with those without HAART (P < 0.01), although the clinical efficacy did not correlate with HIV-1 VL. HAART may enhance the immunologic efficacy of influenza vaccine.
| Original language | English |
|---|---|
| Pages (from-to) | 167-173 |
| Number of pages | 7 |
| Journal | Journal of Acquired Immune Deficiency Syndromes |
| Volume | 39 |
| Issue number | 2 |
| Publication status | Published - 2005 Jun 1 |
Fingerprint
Keywords
- Antibody response
- HIV-1
- Influenza
- Specific CD4
- Vaccination
ASJC Scopus subject areas
- Virology
- Immunology
Cite this
Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. / Yamanaka, Hikaru; Teruya, Katsuji; Tanaka, Mari; Kikuchi, Yoshimi; Takahashi, Takao; Kimura, Satoshi; Oka, Shinichi.
In: Journal of Acquired Immune Deficiency Syndromes, Vol. 39, No. 2, 01.06.2005, p. 167-173.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients
AU - Yamanaka, Hikaru
AU - Teruya, Katsuji
AU - Tanaka, Mari
AU - Kikuchi, Yoshimi
AU - Takahashi, Takao
AU - Kimura, Satoshi
AU - Oka, Shinichi
PY - 2005/6/1
Y1 - 2005/6/1
N2 - Influenza vaccine is recommended for HIV-1-infected patients. The present prospective study was conducted to evaluate the clinical efficacy and immunologic responses to the vaccine, From November 1 to December 27, 2002, 262 HIV-1-infected patients received a trivalent influenza subunit vaccine, whereas 66 did not. Influenza illness occurred in 16 vaccinated and 14 nonvaccinated patients (incidence = 6.1% [95% confidence interval (CI): 4%-10%] in vaccinated vs. 21.2% [CI: 13%-35%] in nonvaccinated persons, P < 0.001; relative risk = 0.29 [CI: 0.14-0.55]). Influenza vaccine provided clinically effective protection against influenza illness in HIV-1-infected patients. In baseline antibody-negative patients, anti-H1 and anti-H3 antibody responses to the vaccination were significant in those patients with a CD4 count > 200 cells/μL compared with those with a CD4 count <200 cells/μL (P < 0.05). In contrast, in baseline antibody-positive patients, good antibody responses were observed irrespective of CD4 counts, like the healthy controls. Based on these results, annual vaccination is recommended. Specific CD4 responses correlated with HIV-1 viral load (VL), especially in patients treated with highly active antiretroviral therapy (HAART) compared with those without HAART (P < 0.01), although the clinical efficacy did not correlate with HIV-1 VL. HAART may enhance the immunologic efficacy of influenza vaccine.
AB - Influenza vaccine is recommended for HIV-1-infected patients. The present prospective study was conducted to evaluate the clinical efficacy and immunologic responses to the vaccine, From November 1 to December 27, 2002, 262 HIV-1-infected patients received a trivalent influenza subunit vaccine, whereas 66 did not. Influenza illness occurred in 16 vaccinated and 14 nonvaccinated patients (incidence = 6.1% [95% confidence interval (CI): 4%-10%] in vaccinated vs. 21.2% [CI: 13%-35%] in nonvaccinated persons, P < 0.001; relative risk = 0.29 [CI: 0.14-0.55]). Influenza vaccine provided clinically effective protection against influenza illness in HIV-1-infected patients. In baseline antibody-negative patients, anti-H1 and anti-H3 antibody responses to the vaccination were significant in those patients with a CD4 count > 200 cells/μL compared with those with a CD4 count <200 cells/μL (P < 0.05). In contrast, in baseline antibody-positive patients, good antibody responses were observed irrespective of CD4 counts, like the healthy controls. Based on these results, annual vaccination is recommended. Specific CD4 responses correlated with HIV-1 viral load (VL), especially in patients treated with highly active antiretroviral therapy (HAART) compared with those without HAART (P < 0.01), although the clinical efficacy did not correlate with HIV-1 VL. HAART may enhance the immunologic efficacy of influenza vaccine.
KW - Antibody response
KW - HIV-1
KW - Influenza
KW - Specific CD4
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=19644367545&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19644367545&partnerID=8YFLogxK
M3 - Article
C2 - 15905732
AN - SCOPUS:19644367545
VL - 39
SP - 167
EP - 173
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
SN - 1525-4135
IS - 2
ER -